190 related articles for article (PubMed ID: 36173579)
21. Transgenic mice for in vivo epigenome editing with CRISPR-based systems.
Gemberling MP; Siklenka K; Rodriguez E; Tonn-Eisinger KR; Barrera A; Liu F; Kantor A; Li L; Cigliola V; Hazlett MF; Williams CA; Bartelt LC; Madigan VJ; Bodle JC; Daniels H; Rouse DC; Hilton IB; Asokan A; Ciofani M; Poss KD; Reddy TE; West AE; Gersbach CA
Nat Methods; 2021 Aug; 18(8):965-974. PubMed ID: 34341582
[TBL] [Abstract][Full Text] [Related]
22. DNA epigenome editing using CRISPR-Cas SunTag-directed DNMT3A.
Huang YH; Su J; Lei Y; Brunetti L; Gundry MC; Zhang X; Jeong M; Li W; Goodell MA
Genome Biol; 2017 Sep; 18(1):176. PubMed ID: 28923089
[TBL] [Abstract][Full Text] [Related]
23. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
Tadić V; Josipović G; Zoldoš V; Vojta A
Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
[TBL] [Abstract][Full Text] [Related]
24.
Liang F; Dong Z; Ye J; Hu W; Bhandari RK; Mai K; Wang X
Epigenetics; 2023 Dec; 18(1):2192326. PubMed ID: 36945831
[TBL] [Abstract][Full Text] [Related]
25. Chemical and Light Inducible Epigenome Editing.
Zhao W; Wang Y; Liang FS
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32028669
[TBL] [Abstract][Full Text] [Related]
26. A Review on CRISPR-mediated Epigenome Editing: A Future Directive for Therapeutic Management of Cancer.
Chakravarti R; Lenka SK; Gautam A; Singh R; Ravichandiran V; Roy S; Ghosh D
Curr Drug Targets; 2022; 23(8):836-853. PubMed ID: 35078394
[TBL] [Abstract][Full Text] [Related]
27. Precise epigenomic editing with a SunTag-based modular epigenetic toolkit.
Guhathakurta S; Adams L; Jeong I; Sivakumar A; Cha M; Bernardo Fiadeiro M; Hu HN; Kim YS
Epigenetics; 2022 Dec; 17(13):2075-2081. PubMed ID: 35920441
[TBL] [Abstract][Full Text] [Related]
28. Unraveling the functional role of DNA demethylation at specific promoters by targeted steric blockage of DNA methyltransferase with CRISPR/dCas9.
Sapozhnikov DM; Szyf M
Nat Commun; 2021 Sep; 12(1):5711. PubMed ID: 34588447
[TBL] [Abstract][Full Text] [Related]
29. Efficient Targeted DNA Methylation with dCas9-Coupled DNMT3A-DNMT3L Methyltransferase.
Bashtrykov P; Rajaram N; Jeltsch A
Methods Mol Biol; 2023; 2577():177-188. PubMed ID: 36173573
[TBL] [Abstract][Full Text] [Related]
30. Targeted in vivo epigenome editing of H3K27me3.
Fukushima HS; Takeda H; Nakamura R
Epigenetics Chromatin; 2019 Mar; 12(1):17. PubMed ID: 30871638
[TBL] [Abstract][Full Text] [Related]
31. Programmable targeted epigenetic editing using CRISPR system in Bombyx mori.
Liu Y; Ma S; Chang J; Zhang T; Chen X; Liang Y; Xia Q
Insect Biochem Mol Biol; 2019 Jul; 110():105-111. PubMed ID: 31022512
[TBL] [Abstract][Full Text] [Related]
32. Development of super-specific epigenome editing by targeted allele-specific DNA methylation.
Rajaram N; Kouroukli AG; Bens S; Bashtrykov P; Jeltsch A
Epigenetics Chromatin; 2023 Oct; 16(1):41. PubMed ID: 37864244
[TBL] [Abstract][Full Text] [Related]
33. A modular dCas9-SunTag DNMT3A epigenome editing system overcomes pervasive off-target activity of direct fusion dCas9-DNMT3A constructs.
Pflueger C; Tan D; Swain T; Nguyen T; Pflueger J; Nefzger C; Polo JM; Ford E; Lister R
Genome Res; 2018 Aug; 28(8):1193-1206. PubMed ID: 29907613
[TBL] [Abstract][Full Text] [Related]
34. Editing the Epigenome: Overview, Open Questions, and Directions of Future Development.
Rots MG; Jeltsch A
Methods Mol Biol; 2018; 1767():3-18. PubMed ID: 29524127
[TBL] [Abstract][Full Text] [Related]
35. Epigenome editing in cancer: Advances and challenges for potential therapeutic options.
Lee SW; Frankston CM; Kim J
Int Rev Cell Mol Biol; 2024; 383():191-230. PubMed ID: 38359969
[TBL] [Abstract][Full Text] [Related]
36. CRISPR-mediated modification of DNA methylation pattern in the new era of cancer therapy.
Maroufi F; Maali A; Abdollahpour-Alitappeh M; Ahmadi MH; Azad M
Epigenomics; 2020 Oct; 12(20):1845-1859. PubMed ID: 33185489
[TBL] [Abstract][Full Text] [Related]
37. Targeting epigenetic aberrations of sarcoma in CRISPR era.
Tanaka M; Nakamura T
Genes Chromosomes Cancer; 2023 Sep; 62(9):510-525. PubMed ID: 36967299
[TBL] [Abstract][Full Text] [Related]
38. Epigenome Editing in the Brain.
Bashtrykov P; Jeltsch A
Adv Exp Med Biol; 2017; 978():409-424. PubMed ID: 28523558
[TBL] [Abstract][Full Text] [Related]
39. Regulation of gene expression by altered promoter methylation using a CRISPR/Cas9-mediated epigenetic editing system.
Kang JG; Park JS; Ko JH; Kim YS
Sci Rep; 2019 Aug; 9(1):11960. PubMed ID: 31427598
[TBL] [Abstract][Full Text] [Related]
40. Toward the Development of Epigenome Editing-Based Therapeutics: Potentials and Challenges.
Ueda J; Yamazaki T; Funakoshi H
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
